Roivant Sciences is trading 23.81% lower at $29.12 after-hours on September 22, 2026, versus the regular-session close of $38.22; available coverage identifies no specific negative announcement explaining the decline. - At the Bank of America Global Healthcare Conference, the company discussed its pipeline, LISRAYA launch, and upcoming clinical readouts. - The broader market was mixed, with no clear macro catalyst evident.